This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. “Compound 6” (Novartis) is a first-in-class YAP-TEAD protein-protein inhibitor. The TEAD transcription factor and its coactivator YAP and WWTR1/TAZ…
molecule
6 months ago ●
4 mins read
Merck’s oral, macrocyclic PCSK9 inhibitors are among the 12 candidates for 2021's "Molecule of the Year" and have already gotten…
Article
1 year ago ●
2 mins read
Context. GNE-064 (Genentech) is an oral inhibitor of the bromodomains of SMARCA2/4 and PBRM1 being developed as a tool compound.…
molecule
6 months ago ●
4 mins read
The FDA recently approved Agios' Pyrukynd (mitapivat, AG-348), a first-in-class, allosteric activator of pyruvate kinase (PK), for treatment of hemolytic…
Article
1 year ago ●
3 mins read
Context. “Compound 33” (Merck) is a cGMP-dependent protein kinase G1α (PKG1α) activator cGMP modulation is considered one of the most…
molecule
7 months ago ●
5 mins read
together with Dr. Jennifer Huen, Saumil Patel, and Dr. Naveed Yasin In 2021, the FDA approved 9 non-radiological novel small…
Article
1 year ago ●
18 mins read
Load More
